Queen Elizabeth Hospital
Hospital
Location:
London,
United Kingdom (GB)
ISNI: 0000000403984383
ROR: https://ror.org/00p6q5476
Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022)
Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al.
Conference contribution
Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients (2021)
Fuchs TL, Maclean F, Turchini J, Vargas AC, Bhattarai S, Agaimy A, Hartmann A, et al.
Journal article
CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen (2020)
Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , et al.
Conference contribution
Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019)
Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al.
Journal article
Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry (2018)
Lee M, Wlodarczak A, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, et al.
Conference contribution
Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score (2018)
Holtsche MM, Goletz S, Van Beek N, Zillikens D, Benoit S, Harman K, Walton S, et al.
Journal article
Doxycycline versus Prednisolone for the initial Treatment of bullous Pemphigoids: a pragmatic prospective randomized Study (2017)
Schmidt E, Benoit S, Ehrchen J, Glaeser R, Guenther C, Steinbrink K, Sticherling M, et al.
Conference contribution